Mounjaro Cardiovascular Data

The cardiovascular story for tirzepatide is less developed than the story for semaglutide, but the direction is clear. The medication appears to reduce cardiovascular events in people with type 2 diabetes, and trials are underway in broader populations. In South Africa, the cardiovascular indication has not yet been formalised by SAHPRA, but the data is moving in a positive direction.

This page is an editorial summary of where the evidence currently stands, what it means in practice, and what is still to come.

Why Cardiovascular Data Matters

Most people who develop obesity or type 2 diabetes do not die from those conditions directly. They die from the cardiovascular consequences: heart attacks, strokes, heart failure, and cardiovascular complications. Reducing weight or improving blood sugar matters mainly because those changes are expected to translate into reduced cardiovascular events.

For decades, weight management medications were approved based on weight reduction alone, with cardiovascular benefits assumed but not directly tested. Some older weight loss medications were later found to increase cardiovascular events despite producing weight loss, which led to a fundamental shift in how new medications are evaluated. Cardiovascular outcome trials are now expected for any medication of this class.

The SURPASS-CVOT Trial

SURPASS-CVOT was the cardiovascular outcomes trial for tirzepatide in people with type 2 diabetes. It enrolled over 13,000 adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors. Participants were randomised to either tirzepatide or dulaglutide (an older GLP-1 medication with established cardiovascular safety). Follow up averaged several years.

The headline results, reported in 2025, showed that tirzepatide was non-inferior to dulaglutide on the composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke. Emerging secondary analyses suggested possible superiority on individual endpoints, though the trial was not powered to demonstrate this definitively.

What The Results Mean In Practice

For people with type 2 diabetes and cardiovascular risk, the data supports tirzepatide as a cardiovascular safety neutral and probably beneficial choice. The combination of strong glucose control (from the SURPASS programme), strong weight reduction (from the SURMOUNT programme), and confirmed cardiovascular safety (from SURPASS-CVOT) is a strong case for use in this population.

For people without type 2 diabetes who have cardiovascular disease and excess weight, the picture is less complete. The cardiovascular outcomes specifically in non-diabetic populations have not been published yet. Wegovy holds the formal cardiovascular indication for this group, based on the SELECT trial. Many specialists currently lean toward Wegovy for this specific use case.

The Mechanism Behind Cardiovascular Benefit

The mechanisms by which tirzepatide reduces cardiovascular risk are likely multifactorial:

• Weight reduction reduces cardiovascular load and improves multiple risk factors
• Blood pressure reduction of several mmHg occurs consistently in trials
• Improved blood sugar reduces vascular damage over years
• Lipid profile improvements particularly in triglycerides
• Reduced inflammation as measured by markers like hs-CRP
• Possible direct vascular effects through GLP-1 receptors on blood vessel walls

None of these mechanisms is unique to tirzepatide. All GLP-1 medications show similar effects. The question is whether the dual mechanism adds anything beyond the GLP-1-only medications, and the current data suggests at minimum equivalent benefit, with possible additional benefit that ongoing trials will clarify.

What Is Still Uncertain

Three significant unknowns remain in the cardiovascular story for tirzepatide:

1. Non-diabetic populations

The SURPASS-CVOT trial was in people with type 2 diabetes. The cardiovascular benefit specifically in people with obesity but without diabetes is being studied in SURMOUNT-MMO (Mounjaro Major Outcomes), which has not yet reported.

2. Primary prevention

Both the diabetes and weight management trials enrolled people with elevated cardiovascular risk or established disease. The benefit in people with risk factors but no established disease is less directly studied.

3. Comparison to semaglutide on cardiovascular endpoints

Head to head cardiovascular outcome trials between tirzepatide and semaglutide do not exist. Comparing across separate trials suggests the medications are roughly similar on cardiovascular outcomes in their respective populations, but a direct trial would settle the question more definitively.

The Regulatory Status In South Africa

SAHPRA registered Mounjaro for type 2 diabetes in December 2024 and for chronic weight management in October 2025. A specific cardiovascular indication has not been formally added. The medication can be used for the registered indications, and cardiovascular benefit, where applicable, is considered a secondary effect rather than an explicit prescribing reason.

This is a regulatory state of affairs, not a clinical limitation. Doctors prescribing tirzepatide for type 2 diabetes are implicitly accepting the cardiovascular benefit as part of the package. For weight management in patients with cardiovascular disease, the conversation includes the trial data even if the SA registration does not yet explicitly include it.

Frequently Asked